How Wells Fargo Currently Rates Intercept Pharma (NASDAQ:ICPT)
In a recent research report revealed on Friday morning, Wells Fargo analyst just have started coverage of Intercept Pharma (NASDAQ:ICPT) with Market Perform rating.
From a total of 15 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT) stock, 11 rate it a ”Buy”, 2 a “Sell”, and 2 a ”Hold”. This means that 73% of the ratings are positive. The highest target price is $515 while the lowest target price is $110. The mean of all analyst targets is $358 with a 51.51% above today’s ($153.1) stock price. Intercept Pharmaceuticals was the topic of 8 analyst reports since August 10, 2015 according to the firm StockzIntelligence Inc. Oppenheimer maintained shares on November 18 with “Outperform” rating. Bank of America downgraded ICPT stock in a recent report from October 28 to “Underperform” rating. Finally, Morgan Stanley initiated the stock with “Underweight” rating in a report issued on an August 13.
Approximately 70,688 shares of stock traded hands. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has declined 38.78% since May 1, 2015 and is downtrending. It has underperformed by 36.00% the S&P500.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $3.73 billion. The Firm is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. It currently has negative earnings. The Company’s product candidate, obeticholic acid , is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
According to Zacks Investment Research, “Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company’s lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. is headquartered in New York.” Get a free copy of the Zacks research report on Intercept Pharmaceuticals Inc (ICPT).